$LH

Summy Amy B. (EVP, Chief Marketing Officer) sold 924 shares of LABCORP HOLDINGS INC. (LH) at $306.74 ($0.28M total) on 2026-08-04.

Labcorp said it has nationwide availability of Roche’s Ventana PTEN (SP218) RxDx immunohistochemistry companion diagnostic, FDA approved to detect PTEN protein loss in prostate adenocarcinoma. The result helps identify patients eligible for AstraZeneca’s TRUQAP (capivasertib) plus abiraterone acetate and prednisone. Labcorp says it supports personalized treatment decisions via its lab network.

Labcorp Holdings (LH) reported Q2 2026 revenue of $3.73B and diluted EPS of $3.64, up from $3.53B and $2.84 a year earlier, according to its 10-Q. The company cited higher test utilization, price and mix gains, and margin expansion, plus 4.2% organic growth and acquisition contributions. It also increased capital spending and completed acquisitions.

Wilkinson Peter J (SVP, Chief Accounting Officer) sold 1,420 shares of LABCORP HOLDINGS INC. (LH) at an average of $309.23 ($309.22–$309.23, $0.44M total) across 2 trades on 2026-08-03.

Court documents say a $35 million class action settlement tied to a 2018-2019 cyberattack on AMCA, a Labcorp billing and collections vendor, may provide cash payouts to eligible patients. Claims are due 3 September, with a final approval hearing set for 20 August. Potential relief includes about $50 per person, up to $5,000 for documented losses, and up to 10 hours of lost time at $25/hour, plus up to two years of medical monitoring, according to the settlement notice.

Labcorp (NYSE:LH) said the FDA-approved Roche VENTANA PTEN (SP218) RxDx Assay is now available nationwide. The test detects PTEN protein loss in prostate adenocarcinoma tissue to identify patients who may qualify for AstraZeneca’s TRUQAP (capivasertib) with abiraterone and prednisone, according to Labcorp. The assay is offered via Labcorp’s lab network.

Labcorp (through a class action) agreed to pay $35 million to resolve claims tied to a cyberattack on AMCA, a billing and collections vendor. The settlement alleges about 7.7 million Labcorp patients’ data may have been exposed. Eligible consumers can file claims until Sept. 3 for cash and free monitoring, after final court approval.

Labcorp (LH) reported Q2 2026 enterprise revenue of $3.7B, up 5.8% YoY, with adjusted EPS of $4.99, up 14.9%. Adjusted operating margin rose to 15.8%. Free cash flow was $314M. The company raised full-year guidance for revenue and adjusted EPS, citing Diagnostics and Central Laboratories strength, and noted ACA headwinds.

Simply Wall St says Labcorp Holdings (LH) reported higher Q2 and first-half sales and net income, raised 2026 revenue growth guidance to 5.4% to 6.3%, and completed a multi-year share repurchase retiring 19.18% of shares for $4.11 billion. It also launched the Marker by Labcorp Genetic Health Panel. The article cites projected 2029 revenue of $16.6B and earnings of $1.4B.

Simply Wall St reports Labcorp Holdings (LH) stock fell about 2% after Q2 results. The company posted Q2 revenue of $3.73b (up 5.8%) and basic EPS of $3.66 (up 28.2%). Trailing net margin rose to 7.0% from 5.7% a year earlier, and management raised full-year revenue and adjusted EPS guidance, citing improved profitability and free cash flow of $314m.